Journal of Cancer Research and Therapeutics Close
 

Figure 2: Case studies of tumor shrinkage rate in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations after the first treatment with tyrosine kinase inhibitors. (a and b) A patient sensitive to tyrosine kinase inhibitors with a progression-free survival of 32.77 months. (c and d) A patient showing limited response to tyrosine kinase inhibitors with a shorter progression-free survival, who was suspected to have primary drug

Figure 2: Case studies of tumor shrinkage rate in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations after the first treatment with tyrosine kinase inhibitors. (a and b) A patient sensitive to tyrosine kinase inhibitors with a progression-free survival of 32.77 months. (c and d) A patient showing limited response to tyrosine kinase inhibitors with a shorter progression-free survival, who was suspected to have primary drug